Design and estimation for evaluating principal surrogate markers in vaccine trials
- PMID: 23409839
- PMCID: PMC3713795
- DOI: 10.1111/biom.12014
Design and estimation for evaluating principal surrogate markers in vaccine trials
Abstract
In vaccine research, immune biomarkers that can reliably predict a vaccine's effect on the clinical endpoint (i.e., surrogate markers) are important tools for guiding vaccine development. This article addresses issues on optimizing two-phase sampling study design for evaluating surrogate markers in a principal surrogate framework, motivated by the design of a future HIV vaccine trial. To address the problem of missing potential outcomes in a standard trial design, novel trial designs have been proposed that utilize baseline predictors of the immune response biomarker(s) and/or augment the trial by vaccinating uninfected placebo recipients at the end of the trial and measuring their immune biomarkers. However, inefficient use of the augmented information can lead to counter-intuitive results on the precision of estimation. To remedy this problem, we propose a pseudo-score type estimator suitable for the augmented design and characterize its asymptotic properties. This estimator has superior performance compared with existing estimators and allows calculation of analytical variances useful for guiding study design. Based on the new estimator we investigate in detail the problem of optimizing the sampling scheme of a biomarker in a vaccine efficacy trial for efficiently estimating its surrogate effect, as characterized by the vaccine efficacy curve (a causal effect predictiveness curve) and by the predicted overall vaccine efficacy using the biomarker.
© 2013, The International Biometric Society.
Figures



Similar articles
-
Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling.Biometrics. 2018 Mar;74(1):27-39. doi: 10.1111/biom.12737. Epub 2017 Jun 26. Biometrics. 2018. PMID: 28653408 Free PMC article.
-
Evaluating candidate principal surrogate endpoints.Biometrics. 2008 Dec;64(4):1146-54. doi: 10.1111/j.1541-0420.2008.01014.x. Epub 2008 Mar 24. Biometrics. 2008. PMID: 18363776 Free PMC article.
-
A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint.Biometrics. 2012 Sep;68(3):922-32. doi: 10.1111/j.1541-0420.2011.01736.x. Epub 2012 Feb 20. Biometrics. 2012. PMID: 22348277 Free PMC article.
-
Some statistical issues in the design of HIV-1 vaccine and treatment trials.Stat Methods Med Res. 2000 Jun;9(3):207-29. doi: 10.1177/096228020000900303. Stat Methods Med Res. 2000. PMID: 11084705 Review.
-
Statistical issues in the design of HIV vaccine trials.Annu Rev Public Health. 1995;16:1-22. doi: 10.1146/annurev.pu.16.050195.000245. Annu Rev Public Health. 1995. PMID: 7639865 Review.
Cited by
-
Evaluation of treatment effect modification by biomarkers measured pre- and post-randomization in the presence of non-monotone missingness.Biostatistics. 2022 Apr 13;23(2):541-557. doi: 10.1093/biostatistics/kxaa040. Biostatistics. 2022. PMID: 32978622 Free PMC article.
-
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.Stat Commun Infect Dis. 2017 Jan;9(1):20160001. doi: 10.1515/scid-2016-0001. Epub 2017 Jun 6. Stat Commun Infect Dis. 2017. PMID: 29218117 Free PMC article.
-
Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial.Nat Commun. 2025 Jul 3;16(1):6118. doi: 10.1038/s41467-025-61153-x. Nat Commun. 2025. PMID: 40610413 Free PMC article. Clinical Trial.
-
Inference on treatment effect modification by biomarker response in a three-phase sampling design.Biostatistics. 2020 Jul 1;21(3):545-560. doi: 10.1093/biostatistics/kxy074. Biostatistics. 2020. PMID: 30590450 Free PMC article.
-
Simultaneous Inference of Treatment Effect Modification by Intermediate Response Endpoint Principal Strata with Application to Vaccine Trials.Int J Biostat. 2019 Jul 2;16(1):/j/ijb.2020.16.issue-1/ijb-2018-0058/ijb-2018-0058.xml. doi: 10.1515/ijb-2018-0058. Int J Biostat. 2019. PMID: 31265429 Free PMC article.
References
-
- Burzykowski T, Molenberghs G, Buyse M. The evaluation of surrogate endpoints. Springer; New York: 2005.
-
- Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1(1):49. - PubMed
-
- Chatterjee N, Chen Y, Breslow N. A pseudoscore estimator for regression problems with two-phase sampling. Journal of the American Statistical Association. 2003;98(461):158–168.
-
- Daniels M, Hughes M. Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine. 1997;16(17):1965–1982. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30CA015704/CA/NCI NIH HHS/United States
- P30 CA015704/CA/NCI NIH HHS/United States
- P01 CA053996/CA/NCI NIH HHS/United States
- U24CA086368/CA/NCI NIH HHS/United States
- R01 GM106177/GM/NIGMS NIH HHS/United States
- R37 AI029168/AI/NIAID NIH HHS/United States
- 2R37AI05465-10/AI/NIAID NIH HHS/United States
- UM1 AI068635/AI/NIAID NIH HHS/United States
- P01CA053996/CA/NCI NIH HHS/United States
- R37 AI054165/AI/NIAID NIH HHS/United States
- U24 CA086368/CA/NCI NIH HHS/United States
- U01 CA086368/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical